Several clinical studies have shown that MM patients treated with the anti-CD38 daratumumab, as well as anti-BCMA bi-specific antibodies, may develop severe hypogammaglobulinemia [85,86,87]. This evidence concerns the gene CD38 and agammaglobulinemia.